Pfizer Q3: The Street Is Pricing In Too Much Deceleration For This 5.7% Yield
Pfizer delivered Q3 2026 revenue of $16.58B and adjusted EPS of $0.87, beating consensus and raising full-year guidance for the second time. I rate PFE stock as Buy.
BTC-4.19%
ETH-5.69%
SOL-6.43%
USDC-0.02%
XRP-5.25%
HYPE-9.47%
SUI-8.58%
GRAMTON-7.17%BTC-4.19%ETH-5.69%SOL-6.43%USDC-0.02%XRP-5.25%HYPE-9.47%SUI-8.58%GRAMTON-7.17%BTC-4.19%ETH-5.69%SOL-6.43%USDC-0.02%XRP-5.25%HYPE-9.47%SUI-8.58%GRAMTON-7.17%BTC-4.19%ETH-5.69%SOL-6.43%USDC-0.02%XRP-5.25%HYPE-9.47%SUI-8.58%GRAMTON-7.17%
